IL6 and infection: Third, the management of patients with severe COVID-19 has evolved since recruitment closing; while the early use of dexamethasone does not appear to increase the risk of VAP [46], other specific therapies such as anti-IL6 drugs might have modified the epidemiology of ICU-acquired infections [47]. Fourth, the relatively low number of COVID-19 patients could have precluded the detection of a significant effect of VAP on mortality in this subgroup.